Novo Nordisk Stock Skids As Report Finds ‘Objectionable’ Conditions At A Key Wegovy Plant

Novo Nordisk (NVO) stock skidded Monday on reports a Food and Drug Administration inspection turned up “objectionable conditions” at a facility charged with making diabetes and weight-loss drugs.


According to Reuters — which cited a Market Wire News report — the FDA inspectors filed a Form 483 following their inspection of Novo Nordisk’s Clayton, N.C., manufacturing plant. That form lists any conditions the inspector found that could violate the Food and Drug Cosmetic Act and…

Read More